Yangzijiang winning products soared 180 times 13 pounds to prepare for the third round of harvesting.

Pharmaceutical network August 18th, the national drug collection after the 2018 4 plus 7 city pilot, 2019 alliance expansion, and then to 2020 the second round of national collection, after the actual practice of grinding and adjustment, whether it is the selection of procurement varieties, or agreed procurement statistics, and even the adjustment of bidding rules are increasingly reasonable and mature, the third round will be opened on August 20, 56 varieties will usher in the first price ... After the first two rounds (three times) of price fighting, the exclusive winning bid, "barefoot" (i.e., the original market share is less or not yet entered the market products) lying to win and so on stimulate a number of winning enterprises' performance rise, the policy is good under the third round of collection to participate in the number of enterprises is expected to reach a new high.
YangZiJiang in the first round (4 plus 7, the expansion of the alliance) has two products exclusive bid, followed by the second round of the winning products up to 4, the third round is expected to have 13 products to participate in the bidding, the collection of "seed player" why so actively participate? What heavyweight products are expected to participate in future harvesting? 6 major products forward collection, exclusive winning bid sales surge 180 times Table 1: Yangzijiang has participated in the national collection of products source: MED2.0 China drug review database Figure 1: the first round of collection of Yangzijiang winning product market share change source: Minnet China public medical institutions terminal competition pattern Yangzijiang's Maly acid Inapuri film is According to the supplementary application declaration consistency evaluation was approved, the product in 2017 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of 180 million, market share of nearly 45%, after the first round of collection, sales in 2019 rose to 260 million yuan, market share of more than 51%, the growth rate is fast.
hydrochloric acid right meetumide injection is approved according to the new classification and as a review, the product was approved in June 2018, after the enterprise's market share of 0, belongs to the "barefoot" varieties, after winning the bid market quickly released, leapt into 20 Sales of more than 1 billion products in 19 years soared by 18,114.75 percent and market share rose to 33 percent, while the market share of former leader Hengrui fell from 84.22 percent in 2017 to 53.21 percent in 2019.
Table 2: Market share of the second round of national collection products in China's public medical institutions terminals in 2019 Source: Minnet China's public medical institutions terminal competition pattern of the second round of collection in April 2020 in the provinces, the overall market situation has not yet been known, but according to Jiangxi Province announced In this case, the province has been officially implemented since April 11, as of June 30, the total quantity of 36 product regulations accounted for 82.36 percent of the total amount of agreed procurement, 11 rules to complete the agreed procurement quantity, 17 rules to complete the progress of more than 50 percent.
, Yangzijiang won the bid jiangxi Province's products are Grameen tablets and Meloxikang tablets, the completion progress of 76.65 percent, 67.39 percent, respectively, satisfactory results.
13 products to participate in the third round of collection, 7 new batches of listings are expected to quickly occupy the market Table 3: is expected to participate in the third round of national collection of products and competitors source: MNE NETWORK MED2.0 China drug review database Yangzijiang into the third round of collection catalog products have 13 (non-nathylamine tablets by different adaptations separate quotation, so this article is analyzed by 2 products Among them approved according to the new classification involving Viglitin tablets,acid tofatib tablets, non-neutrosamine tablets (1mg), trigrelo tablets, Monrust sodium chewing tablets, hydrochloric acid mei King Kong tablets, left oxyfluorostar eye drops, these 7 new products were in the market earlier blank, if successful, can quickly enter the market.
Table 4: Top three regional sources of agreed purchase volume for the first year of the seven major products: National Drug Central Procurement Document (GY-YD2020-1) from the regional agreed procurement volume, Yangzijiang's 7 new batch of listed products if selected Guangdong, Zhejiang, Jiangsu and other procurement volume Large areas, the product rapid release of the odds are very large, if theacid tofatib cloth tablets, non-amine tablets (1mg) and Monrust sodium chewing tablets (4mg) OF3 areas are taken down, half of the mountain on the bag for ann.
sets of products to promote normalization, Yangzijiang 10 over-rated products are on standby rice in-network data show that as of August 17, 2020, Yangzijiang over-evaluation or the same as the evaluation of 35 products, of which 7 belong to the first and second round of catalog scope but did not win the bid of products, 6 have been included in the collection, 13 bids for the third round, the remaining will have the opportunity to be included in the collection? Table 5: Products that have been evaluated but have not yet been included in the national collection source: MED2.0 China Drug Review Database with the continuous progress of consistency evaluation work, the number of over-rated products continues to improve, the national collection has also entered the normal, included The procurement catalog of varieties round than round more, in order to cope with the New Deal and maintain market leading edge, the domestic pharmaceutical giant's generic drug research and development is also accelerating, the current Yangzijiang has been evaluated but not included in the collection of products, related reviews The number of enterprises has reached 3 (including) more than 6, after reaching full competition is likely to be the next round or the next round of collection "phase", Minet data show that 2019 in China's public medical institutions terminal Devashaban tablets and glass Sodium sodium drops are more than 1 billion products, while chlorretadamine tablets, rinalide capsules, achimycin tablets, and cephalosporine lartin capsules are also over 100 million grade products, these heavy products are the way to collect or near.
source: Mi in-network database, Shanghai Sunshine Pharmaceutical Procurement Network review data statistics as of August 17, 2020, if there are errors, please point out.